Literature DB >> 26627830

His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor.

Emilie Leroy1, Jean-Philippe Defour1, Takeshi Sato2, Sharmila Dass3, Vitalina Gryshkova1, Myat M Shwe1, Judith Staerk4, Stefan N Constantinescu5, Steven O Smith6.   

Abstract

Ligand binding to the extracellular domain of the thrombopoietin receptor (TpoR) imparts a specific orientation on the transmembrane (TM) and intracellular domains of the receptors that is required for physiologic activation via receptor dimerization. To map the inactive and active dimeric orientations of the TM helices, we performed asparagine (Asn)-scanning mutagenesis of the TM domains of the murine and human TpoR. Substitution of Asn at only one position (S505N) activated the human receptor, whereas Asn substitutions at several positions activated the murine receptor. Second site mutational studies indicate that His(499) near the N terminus of the TM domain is responsible for protecting the human receptor from activation by Asn mutations. Structural studies reveal that the sequence preceding His(499) is helical in the murine receptor but non-helical in peptides corresponding to the TM domain of the inactive human receptor. The activating S505N mutation and the small molecule agonist eltrombopag both induce helix in this region of the TM domain and are associated with dimerization and activation of the human receptor. Thus, His(499) regulates the activation of human TpoR and provides additional protection against activating mutations, such as oncogenic Asn mutations in the TM domain.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Mpl; TpoR; cell biology; cytokine; hematopoiesis; membrane biophysics; receptor structure-function; signal transduction; thrombopoietin receptor; transmembrane domain

Mesh:

Substances:

Year:  2015        PMID: 26627830      PMCID: PMC4742759          DOI: 10.1074/jbc.M115.696534

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Juxtamembrane autoinhibition in receptor tyrosine kinases.

Authors:  Stevan R Hubbard
Journal:  Nat Rev Mol Cell Biol       Date:  2004-06       Impact factor: 94.444

2.  Model for growth hormone receptor activation based on subunit rotation within a receptor dimer.

Authors:  Richard J Brown; Julian J Adams; Rebecca A Pelekanos; Yu Wan; William J McKinstry; Kathryn Palethorpe; Ruth M Seeber; Thea A Monks; Karin A Eidne; Michael W Parker; Michael J Waters
Journal:  Nat Struct Mol Biol       Date:  2005-08-21       Impact factor: 15.369

3.  Polarized infrared spectroscopy of oriented purple membrane.

Authors:  K J Rothschild; N A Clark
Journal:  Biophys J       Date:  1979-03       Impact factor: 4.033

4.  Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule.

Authors:  H Matsushime; L H Wang; M Shibuya
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

5.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

6.  Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications.

Authors:  Samantha L Gadd; Charles V Clevenger
Journal:  Mol Endocrinol       Date:  2006-07-13

7.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

Authors:  J Downward; Y Yarden; E Mayes; G Scrace; N Totty; P Stockwell; A Ullrich; J Schlessinger; M D Waterfield
Journal:  Nature       Date:  1984 Feb 9-15       Impact factor: 49.962

8.  A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis.

Authors:  Takanori Nakamura; Yoshitaka Miyakawa; Atsushi Miyamura; Akiko Yamane; Hidenori Suzuki; Mamoru Ito; Yasuyuki Ohnishi; Norihisa Ishiwata; Yasuo Ikeda; Nobutomo Tsuruzoe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

9.  Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.

Authors:  Jianmin Ding; Hirokazu Komatsu; Atsushi Wakita; Miyuki Kato-Uranishi; Masato Ito; Atsushi Satoh; Kazuya Tsuboi; Masakazu Nitta; Hiroshi Miyazaki; Shinsuke Iida; Ryuzo Ueda
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

10.  Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.

Authors:  Nadine Seubert; Yohan Royer; Judith Staerk; Katharina F Kubatzky; Virginie Moucadel; Shyam Krishnakumar; Steven O Smith; Stefan N Constantinescu
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

View more
  10 in total

1.  Eltrombopag, a potent stimulator of megakaryopoiesis.

Authors:  Hana Raslova; William Vainchenker; Isabelle Plo
Journal:  Haematologica       Date:  2016-12       Impact factor: 9.941

2.  An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis.

Authors:  J-P Defour; Y Hoade; A-M Reuther; A Callaway; D Ward; F Chen; S N Constantinescu; N C P Cross
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

Review 3.  In and out: Traffic and dynamics of thrombopoietin receptor.

Authors:  Anita Roy; Saurabh Shrivastva; Saadia Naseer
Journal:  J Cell Mol Med       Date:  2021-08-27       Impact factor: 5.295

4.  Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.

Authors:  Thomas Balligand; Younes Achouri; Christian Pecquet; Gilles Gaudray; Didier Colau; Eva Hug; Yacine Rahmani; Vincent Stroobant; Isabelle Plo; William Vainchenker; Robert Kralovics; Benoît J Van den Eynde; Jean-Philippe Defour; Stefan N Constantinescu
Journal:  Leukemia       Date:  2019-08-30       Impact factor: 11.528

5.  Spiers Memorial Lecture: Analysis and de novo design of membrane-interactive peptides.

Authors:  Huong T Kratochvil; Robert W Newberry; Bruk Mensa; Marco Mravic; William F DeGrado
Journal:  Faraday Discuss       Date:  2021-12-24       Impact factor: 4.394

Review 6.  Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.

Authors:  Isabelle Plo; Christine Bellanné-Chantelot; Matthieu Mosca; Stefania Mazzi; Caroline Marty; William Vainchenker
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-12       Impact factor: 5.555

Review 7.  The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin.

Authors:  Leila N Varghese; Jean-Philippe Defour; Christian Pecquet; Stefan N Constantinescu
Journal:  Front Endocrinol (Lausanne)       Date:  2017-03-31       Impact factor: 5.555

8.  Two activating mutations of MPL in triple-negative myeloproliferative neoplasms.

Authors:  Juan Xie; Xiuhua Chen; Feng Gao; Ruixia Hou; Tingting Tian; Yaofang Zhang; Lifang Fan; Jinjun Hu; Guiyang Zhu; Wanfang Yang; Hongwei Wang
Journal:  Cancer Med       Date:  2019-07-11       Impact factor: 4.452

Review 9.  The thrombopoietin receptor: revisiting the master regulator of platelet production.

Authors:  Ian S Hitchcock; Maximillian Hafer; Veena Sangkhae; Julie A Tucker
Journal:  Platelets       Date:  2021-06-07       Impact factor: 3.862

Review 10.  Functional Consequences of Mutations in Myeloproliferative Neoplasms.

Authors:  Stefan N Constantinescu; William Vainchenker; Gabriel Levy; Nicolas Papadopoulos
Journal:  Hemasphere       Date:  2021-06-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.